43 related articles for article (PubMed ID: 11322264)
1. VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.
Lori F; De Forni D; Katabira E; Baev D; Maserati R; Calarota SA; Cahn P; Testori M; Rakhmanova A; Stevens MR
PLoS One; 2012; 7(10):e47485. PubMed ID: 23094055
[TBL] [Abstract][Full Text] [Related]
2. Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS.
De Forni D; Stevens MR; Lori F
Br J Pharmacol; 2010 Oct; 161(4):830-43. PubMed ID: 20860662
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox.
Inayat MS; El-Amouri IS; Bani-Ahmad M; Elford HL; Gallicchio VS; Oakley OR
J Inflamm (Lond); 2010 Aug; 7():43. PubMed ID: 20718971
[TBL] [Abstract][Full Text] [Related]
4. Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.
Swindells S; Cohen CJ; Berger DS; Tashima KT; Liao Q; Pobiner BF; Snidow JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Apr; 5():23. PubMed ID: 15819974
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.
Lisziewicz J; Foli A; Wainberg M; Lori F
Drug Saf; 2003; 26(9):605-24. PubMed ID: 12814330
[TBL] [Abstract][Full Text] [Related]
6. Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV.
Balzarini J; Camarasa MJ; Pérez-Pérez MJ; San-Félix A; Velázquez S; Perno CF; De Clercq E; Anderson JN; Karlsson A
J Virol; 2001 Jul; 75(13):5772-7. PubMed ID: 11390579
[TBL] [Abstract][Full Text] [Related]
7. Didanosine: an updated review of its use in HIV infection.
Perry CM; Noble S
Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
[TBL] [Abstract][Full Text] [Related]
8. New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.
Ravot E; Lisziewicz J; Lori F
Drugs; 1999 Dec; 58(6):953-63. PubMed ID: 10651384
[TBL] [Abstract][Full Text] [Related]
9. The role of didanosine in the management of HIV-1 infection.
Gazzard BG; Moyle GJ
Antivir Ther; 1997 Jul; 2(3):135-47. PubMed ID: 11322269
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.
Lori F; Lisziewicz J
Antivir Ther; 1999; 4 Suppl 3():101-8. PubMed ID: 16021881
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J
Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
[TBL] [Abstract][Full Text] [Related]
14. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
Clotet B; Ruiz L; Cabrera C; Ibáñez A; Cañadas MP; Sirera G; Romeu J; Vila J
Antivir Ther; 1996 Aug; 1(3):189-93. PubMed ID: 11322253
[TBL] [Abstract][Full Text] [Related]
15. Zidovudine plus didanosine in primary HIV-1 infection.
Perrin L; Yerly S; Charvier A; Figueras G; Schockmel GA; Hirschel B
Antivir Ther; 1997 Jan; 2(1):5-11. PubMed ID: 11322267
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
